<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04186767</url>
  </required_header>
  <id_info>
    <org_study_id>86158918.4.0000.0068</org_study_id>
    <nct_id>NCT04186767</nct_id>
  </id_info>
  <brief_title>Weight Loss Impact on Male Fertility</brief_title>
  <official_title>Significative Weight Loss Impact on Oxidative Stress, Metabolic, Hormonal, Inflammatory and Seminal Parameters of Obese Men.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective non-randomized unicentric clinical trial, characterized by the
      inclusion of obese (BMI&gt; 35) male with subfertility (sperm count showing low sperm counts and
      / or motility and / or morphology and / or DNA fragmentation). Patients selected at the
      endocrinology obesity HC-FMUSP outpatient will be submitted to very low calorie diet (VLCK)
      for 6 months, being reassessed clinically and laboratorially monthly.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 10, 2019</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, unicentre, single group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seminal evaluation</measure>
    <time_frame>Six months</time_frame>
    <description>Spermatic counting will be combined to report</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seminal evaluation</measure>
    <time_frame>Six months</time_frame>
    <description>Spermatic motility will be combined to report</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seminal evaluation</measure>
    <time_frame>Six months</time_frame>
    <description>DNA fragmentation will be combined to report</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolic response</measure>
    <time_frame>Six months</time_frame>
    <description>To evaluate the metabolic parameters lipid and glycemic profiles before and after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal measurements</measure>
    <time_frame>Six months</time_frame>
    <description>To evaluate hormonal parameters total testosterone, LH, FSH, insulin before and after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflamatory response</measure>
    <time_frame>Six months</time_frame>
    <description>To evaluate cytokines TNFa and IL-6 response before and after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue evaluation</measure>
    <time_frame>Six months</time_frame>
    <description>To evaluate adipokines: leptin, adiponectin, UCP-1, FGF21, irisin and PGC1a measures before and after intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota evaluation</measure>
    <time_frame>Six months</time_frame>
    <description>Evaluate the whole intestinal metagenomics before and after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic evaluation</measure>
    <time_frame>Six months</time_frame>
    <description>To evaluate the epigenetic methylation profile of spermatozoa before and after the intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition changes</measure>
    <time_frame>Six months</time_frame>
    <description>Apply body composition digital analyser pre and post intervention.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brow tissue study</measure>
    <time_frame>Six months</time_frame>
    <description>Thermodynamic evaluation of brown adipose tissue using infrared thermography.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adipose tissue toxins study</measure>
    <time_frame>Six months</time_frame>
    <description>Persistent organic pollutants measure: 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Obesity</condition>
  <condition>Sub Fertility, Male</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Weight loss</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Very Low Carb Ketogenic Diet</intervention_name>
    <description>Patients will be submitted to very low-calorie ketogenic dietary intervention (VLCK) according to the recommendations of the Pronokal® Method program including lifestyle and physical activity guidelines. The ketogenic stage (phase 1-3) consists of a VLCD diet (600-800 kcal / d), with low carbohydrate intake and lipids. The amount of high biological value proteins ranges from 0.8 to 1.2 g / kg of body weight / day. This first stage (ketogenic) is maintained until the patient reaches the goal of reducing the target weight by 80% to be reduced, being variable in time, according to the response of each patient. After this period, it evolved to a non-ketogenic stage, initiating the hypocaloric diet (800 to 1500 Kcal), with progressive introduction of other food groups, reducing weight more slowly. The maintenance stage consists of a balanced diet, ranging from 1500 to 2000 Kcal.</description>
    <arm_group_label>Weight loss</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Obesity in male patients

          -  Metabolic Syndrome (NCEP-ATP III)

          -  Alteration of some of the seminal parameters evaluated in conventional seminal
             analysis

        Exclusion Criteria:

          -  Other causes of hypogonadotrophic hypogonadism

               -  Hypergonadotrophic hypogonadism

               -  Contraindications for performance of ketogenic diet:

               -  Type 1 or type 2 diabetes mellitus in insulin use

               -  Food drive

               -  Alcoholism or drug addiction

               -  Severe psychiatric illness

               -  Use of coumarin anticoagulants

               -  Hepatic insufficiency

               -  Severe renal impairment

               -  Hematologic diseases

               -  Cancer in activity,

               -  Cardiovascular or cerebrovascular diseases (arrhythmias, recent myocardial
                  infarction, unstable angina, decompensated heart failure, recent stroke)

               -  Gout

               -  Renal or biliary lithiasis

               -  Major depression or other serious psychiatric illness.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alessandra C Renck, MD</last_name>
    <phone>+5511981211114</phone>
    <email>alerenck@usp.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da USP</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05403000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra C Renck, MD</last_name>
      <phone>+5511981211114</phone>
      <email>alerenck@usp.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>April 21, 2019</study_first_submitted>
  <study_first_submitted_qc>December 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>December 2, 2019</last_update_submitted>
  <last_update_submitted_qc>December 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Alessandra Renck</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Male</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

